$ABBV AbbVie Q2 Earnings

31 Jul 2026 11:48ABBV
  • Adj. EPS $3.65, est. $3.61, $2.97 y/y
  • Net rev. $16.99B, est. $16.77B
  • Skyrizi rev. $5.51B, est. $5.43B
  • Rinvoq rev. $2.53B, est. $2.48B
  • Humira rev. $756M, est. $734.1M
  • Imbruvica rev. $532M, est. $563.2M
  • YR view incl. $0.14/shr dilutive impact on Apogee deal
  • YR view incl. unfavorable impact of $0.58/shr on IPR&D
  • Sees FY adj. EPS $13.87 to $14.07, saw $13.91 to $14.11
  • Earnings beat estimates as Botox shows signs of revival